Navigation Links
Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints

DENVER--(BUSINESS WIRE)--Apr 24, 2007 - Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP) today announced positive results from its post-clearance marketing study comparing EpiCeram's(TM) efficacy to that of Cutivate(R) cream, a mid-strength topical steroid in the treatment of moderate-to-severe atopic dermatitis (AD).

The study, which took place at five centers, consisted of 113 pediatric patients, with 59 patients receiving treatment with Cutivate(R) and 54 patients receiving treatment with EpiCeram(TM). After 28 days of treatment, the study demonstrated that: -0-

       Both EpiCeram(TM) and Cutivate(R) produced significant

       improvement in patients' conditions after 28 days of treatment;


       There were no statistically significant differences between the

       groups treated with EpiCeram(TM) compared to those treated with

       Cutivate(R) as measured by the SCORAD index at Day 28 (the

       primary outcome measure) or in the percentage of patients

       assessed to be "clear or almost clear" by physician assessment

       at Day 28 (a secondary outcome measure).


       Both EpiCeram(TM) and Cutivate(R) produced significant relief

       from itching (pruritus) and improvement in sleep habits after

       28 days of treatment and that there was no statistically

       significant difference between the two treatments in these

       measures at this time point (both secondary outcome measures).

"The data from this study demonstrate that EpiCeram(TM) is effective and offers both the clinician and parents a new approach for treating atopic dermatitis without the risks often associated with long-term use of topical steroids or immunosuppressants," said Lawrence Charles Parish, M.D., Clinical Professor of Dermatology and Cutaneous Biology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, one of the study's principal investigators.

Atopi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:5/23/2013)... May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... named the 2013 Life Science Firm of the Year by ... Vanda was honored at the TCM,s 25 th Annual ... Maryland.  The Tech Awards Celebration recognizes the leaders and innovators ... Maryland and the surrounding regions. ...
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... Care Conference in Boston.   The live presentation ... Time / 8:20 a.m. Pacific Time.  The presentation will be ... http://www.neurocrine.com . If you are unable ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... (CRL) has invested in a low-dose, state-of-the-art CT machine ... Minnesota.  This advanced diagnostic system will help physicians reach ... care with a radiation dose up to 40% lower ... "The addition of the GE Healthcare Brightspeed Elite CT ...
... ECRI Institute ®, an independent ... improving patient care, today announces the launch of its ... to ECRI Institute,s SELECTplus™ healthcare technology advisory service. The ... intelligence to help hospitals and health systems select and ...
Cached Medicine Technology:Consulting Radiologists, Ltd. Announces Addition of a Low Dose Advanced Computed Tomography (CT) System 2ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions 2ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions 3
(Date:5/23/2013)... Science published an article about bexarotene as a ... starting point for further Alzheimer,s research. The research group ... and KU Leuven in collaboration with the group ... at Janssen Pharmaceutica, Beerse, also tested this candidate drug ... different, as were those of two American study groups. ...
(Date:5/23/2013)... being dragged to its destruction inside a cell, ... signals that thwart the development of tumor-suppressing microRNAs ... early online publication at Nature . , ... tumors, the epidermal growth factor receptor (EGFR) gums ... led by scientists at The University of Texas ...
(Date:5/23/2013)... 23, 2013 The Rottenstein Law Group ... has created the Tylenol Lawsuit Information Center at ... users and those who are considering filing lawsuits. ... potentially cause severe liver damage, according to a 2009 ... In the “safety communication,” the FDA warned consumers against ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
(Date:5/23/2013)... Jeanne Ettelson, president of Beyond OCD , ... free OCD support group in Chicago. Launched in ... the group is lead by psychologists who specialize in ... group participants to learn accurate information about OCD, Cognitive ... in Beyond OCD’s support group benefit from being ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2
... by youngsters with the disease , THURSDAY, July 2 (HealthDay ... to be overweight than those without the disease, increasing their ... is from a major study that explored the weight problems ... common form of the disease that usually shows up in ...
... the launch of (RED)ZONES at the first U2 360 Degrees concert ... rapturous sold out crowd of 90,000 fans. , , ... will be present throughout the U2 tour. The tickets for ... the ticket sales going to the Global Fund to help fund ...
... reports of DEA intervention are accurate, Michael Jackson,s doctors will ... won,t end there. The pharmacists who filled Mr. Jackson,s prescriptions ... name is associated with any of Jackson,s prescriptions," said attorney ... won full federal jury acquittal at trial on a 10 ...
... Cardinal Health today announced that Bruce L. Downey will ... of the planned spinoff of CareFusion Corporation, replacing John B. ... after 22 years of service to the company as a ... chairman and chief executive officer of Barr Pharmaceuticals, Inc. and ...
... the advisory committee,s recommendations to the U.S. Food and Drug Administration (FDA) ... physician leaders from the American Academy of Pain Medicine ... The American Academy of Pain Medicine ... specialty of Pain Medicine, supports the safe and responsible, ...
... the pipeline, could plug a Percocet-Vicodin gap, experts say, , ... Percocet and Vicodin, which a U.S. health advisory panel has ... medical experts contend. , The reason, they say, is that ... Administration advisory panel made its recommendation Tuesday. It followed the ...
Cached Medicine News:Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3Health News:DEA Will Play Hardball in Investigating Michael Jackson's Doctors 2Health News:Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years 2Health News:Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 2Health News:If 2 Painkillers Are Banned, What Next? 2Health News:If 2 Painkillers Are Banned, What Next? 3Health News:If 2 Painkillers Are Banned, What Next? 4
... The Series I Instrument program offers ... low profile, while maintaining strength and durability. ... pathology in tight joint spaces. Series I ... cutting tip style, size and angle required ...
... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ... size and angle required for large and ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
... Punch series facilitates fast and effective resection ... anatomically shaped meniscal rim. The flat, crescent-shaped ... access even the tightest joint spaces. Made ... 20 years of engineering experience in arthroscopy ...
Medicine Products: